Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. 2004

Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
Our Lady of Mercy Cancer Center-Immunology Laboratory, 600 East 233rd St, Bronx, NY 10466, USA. epaietta@earthlink.net

Activating FLT3 mutations are the most common genetic aberrations in acute myeloid leukemia (AML), resulting in the constitutive activation of this receptor tyrosine kinase (RTK), but such mutations are rarely found in acute lymphoblastic leukemia (ALL). Here we describe a unique subset of de novo adult T-cell ALL (T-ALL) cases that coexpress CD117/KIT and cytoplasmic CD3 (CD117/KIT(+) ALL). Activating mutations in the FLT3 RTK gene were found in each of 3 CD117/KIT(+) cases that were analyzed, but not in 52 other adult T-ALL samples from the same series that lacked CD117/KIT expression. Our results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D015971 Gene Expression Regulation, Enzymologic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in enzyme synthesis. Enzymologic Gene Expression Regulation,Regulation of Gene Expression, Enzymologic,Regulation, Gene Expression, Enzymologic
D015973 Gene Expression Regulation, Leukemic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia. Leukemic Gene Expression Regulation,Regulation of Gene Expression, Leukemic,Regulation, Gene Expression, Leukemic
D051941 fms-Like Tyrosine Kinase 3 A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA. Antigens, CD135,CD135 Antigens,CD135 Antigen,Fetal Liver Kinase-2,Fetal Liver Kinase-3,Stem Cell Tyrosine Kinase 1,Antigen, CD135,Fetal Liver Kinase 2,Fetal Liver Kinase 3,fms Like Tyrosine Kinase 3
D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Leukemia, Lymphoblastic,Leukemia, Lymphoid, Acute,Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Lymphocytic Leukemia, Acute,Lymphoma, Lymphoblastic,ALL, Childhood,Acute Lymphoid Leukemia,Leukemia, Acute Lymphoblastic,Leukemia, Lymphoblastic, Acute,Leukemia, Lymphoblastic, Acute, L1,Leukemia, Lymphoblastic, Acute, L2,Leukemia, Lymphoblastic, Acute, Philadelphia-Positive,Leukemia, Lymphocytic, Acute,Leukemia, Lymphocytic, Acute, L1,Leukemia, Lymphocytic, Acute, L2,Lymphoblastic Leukemia, Acute,Lymphoblastic Leukemia, Acute, Adult,Lymphoblastic Leukemia, Acute, Childhood,Lymphoblastic Leukemia, Acute, L1,Lymphoblastic Leukemia, Acute, L2,Lymphocytic Leukemia, L1,Lymphocytic Leukemia, L2,Acute Lymphoblastic Leukemia,Acute Lymphocytic Leukemia,Childhood ALL,L1 Lymphocytic Leukemia,L2 Lymphocytic Leukemia,Leukemia, Acute Lymphocytic,Leukemia, Acute Lymphoid,Leukemia, L1 Lymphocytic,Leukemia, L2 Lymphocytic,Lymphoid Leukemia, Acute,Precursor Cell Lymphoblastic Leukemia Lymphoma
D019009 Proto-Oncogene Proteins c-kit A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis. Antigens, CD117,CD117 Antigens,Receptor, Stem Cell Factor,Stem Cell Factor Receptor,c-kit Protein,c-kit Receptor,kit Proto-Oncogene Protein,p145(c-kit),CD117 Antigen,Proto-Oncogene Protein c-kit,Proto-Oncogene Protein kit,SCF Receptor,p145 c-kit,p145c-kit,Proto Oncogene Protein c kit,Proto Oncogene Protein kit,Proto Oncogene Proteins c kit,Proto-Oncogene Protein, kit,c kit Protein,c kit Receptor,c-kit, Proto-Oncogene Protein,c-kit, Proto-Oncogene Proteins,c-kit, p145,kit Proto Oncogene Protein,p145 c kit,p145c kit
D020794 Receptor Protein-Tyrosine Kinases A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity. PTK Receptor,Receptors, Protein-Tyrosine Kinase,Tyrosine Kinase Linked Receptor,Tyrosine Kinase Linked Receptors,Tyrosine Kinase Receptor,Tyrosine Kinase Receptors,PTK Receptors,Protein-Tyrosine Kinase Receptor,Receptor Protein-Tyrosine Kinase,Kinase Receptor, Tyrosine,Kinase, Receptor Protein-Tyrosine,Kinases, Receptor Protein-Tyrosine,Protein-Tyrosine Kinase Receptors,Protein-Tyrosine Kinase, Receptor,Protein-Tyrosine Kinases, Receptor,Receptor Protein Tyrosine Kinase,Receptor Protein Tyrosine Kinases,Receptor, PTK,Receptor, Protein-Tyrosine Kinase,Receptor, Tyrosine Kinase,Receptors, PTK,Receptors, Protein Tyrosine Kinase

Related Publications

Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
December 2005, Blood,
Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
February 2024, EJHaem,
Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
January 2009, Experimental hematology,
Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
January 1997, Haematologica,
Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
October 2004, Science (New York, N.Y.),
Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
September 2012, Leukemia,
Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
August 2008, Leukemia,
Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
May 2004, Blood,
Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
April 2007, American journal of clinical pathology,
Elisabeth Paietta, and Adolfo A Ferrando, and Donna Neuberg, and John M Bennett, and Janis Racevskis, and Hillard Lazarus, and Gordon Dewald, and Jacob M Rowe, and Peter H Wiernik, and Martin S Tallman, and A Thomas Look
February 2012, American journal of clinical pathology,
Copied contents to your clipboard!